AdAlta and AdCella Partner with SHcell to Globalise Breakthrough CAR-T Cancer Therapy.
AdAlta Limited (ASX: 1AD) and its cellular immunotherapy subsidiary, AdCella, have entered a strategic Development and Collaboration Agreement with Shanghai Cell Therapy Group to co-develop and commercialise BZDS1901 outside Greater China. The deal launches AdCella’s “East to West” strategy, combining Chinese innovation with Australia’s clinical and manufacturing expertise.
BZDS1901 is a first-in-class, PD1-armoured CAR-T therapy targeting mesothelin, a protein highly expressed in aggressive solid tumours such as mesothelioma. Early clinical data from China has demonstrated compelling response rates, including complete responses, alongside a faster and lower-cost manufacturing process compared with conventional CAR-T therapies.
Under the agreement, AdCella will fund and lead development outside China, establish Australian manufacturing, and conduct Phase 1 clinical trials, while SHcell continues development in China. The collaboration provides AdCella exposure to future commercialisation proceeds and positions AdAlta at the forefront of next-generation cellular immunotherapies addressing major unmet needs.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
AdAlta and AdCella Partner with SHcell to Globalise Breakthrough CAR-T Cancer Therapy.
AdAlta Limited (ASX: 1AD) and its cellular immunotherapy subsidiary, AdCella, have entered a strategic Development and Collaboration Agreement with Shanghai Cell Therapy Group to co-develop and commercialise BZDS1901 outside Greater China. The deal launches AdCella’s “East to West” strategy, combining Chinese innovation with Australia’s clinical and manufacturing expertise.
BZDS1901 is a first-in-class, PD1-armoured CAR-T therapy targeting mesothelin, a protein highly expressed in aggressive solid tumours such as mesothelioma. Early clinical data from China has demonstrated compelling response rates, including complete responses, alongside a faster and lower-cost manufacturing process compared with conventional CAR-T therapies.
Under the agreement, AdCella will fund and lead development outside China, establish Australian manufacturing, and conduct Phase 1 clinical trials, while SHcell continues development in China. The collaboration provides AdCella exposure to future commercialisation proceeds and positions AdAlta at the forefront of next-generation cellular immunotherapies addressing major unmet needs.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au